Ikuzawa M, Matsunaga K, Nishiyama S, Nakajima S, Kobayashi Y, Andoh T, Kobayashi A, Ohhara M, Ohmura Y, Wada T
Biomedical Research Laboratories, Kureha Chemical Industries Co., Ltd., Tokyo, Japan.
Int J Immunopharmacol. 1988;10(4):415-23. doi: 10.1016/0192-0561(88)90128-2.
The fate of 14C-labelled PSK in the body was investigated. Although only substances with low mol. wt were observed in blood shortly after the administration, with time, substances with high mol. wt appeared, suggesting absorption of PSK in its original form from the digestive tract. 14C-labelled PSK was distributed in bone marrow, salivary gland, brain liver, spleen, pancreas and tumor. Approximately 70% of 14C-labelled PSK was excreted by expiratory air after 24 h and approximately 15-20% in urine after 72 h. Only a small amount of 14C-labelled PSK was transferred into lymph and bile. The present study on the in vivo behavior of PSK provides an important basis for further analysis of its pharmacological actions.
研究了14C标记的PSK在体内的命运。给药后不久,血液中仅观察到低分子量物质,但随着时间推移,出现了高分子量物质,这表明PSK以其原始形式从消化道吸收。14C标记的PSK分布于骨髓、唾液腺、脑、肝、脾、胰腺和肿瘤中。24小时后,约70%的14C标记的PSK通过呼气排出,72小时后约15 - 20%通过尿液排出。只有少量14C标记的PSK转移至淋巴液和胆汁中。本项关于PSK体内行为的研究为进一步分析其药理作用提供了重要依据。